2. Isotope-Labeled Compounds

Isotope-Labeled Compounds

Isotope-Labeled Compounds

PDF 37.01 MB

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time.

MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds (12242):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17016S1
    Oseltamivir-d3 phosphate 2734920-81-9 98%
    Oseltamivir-d3 (phosphate)eis the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
    Oseltamivir-d3 phosphate
  • HY-170207S
    Aurothioglucose 70%-13C6 98%
    Aurothioglucose 70%-13C6 is the 13C-labeled CRBN ligand-175 (HY-170207).
    Aurothioglucose 70%-13C6
  • HY-17021S2
    Esomeprazole-d3 potassium 98%
    Esomeprazole-d3 potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole-d3 potassium
  • HY-170239S
    Ethyl 2-(4-benzylpiperazin-1-yl)acetate-d8
    Ethyl 2-(4-benzylpiperazin-1-yl)acetate-d8 is the deuterium labeled Ethyl 2-(4-benzylpiperazin-1-yl)acetate (HY-W291375).
    Ethyl 2-(4-benzylpiperazin-1-yl)acetate-d8
  • HY-170244S
    Hexahydro-1,3-isobenzofurandione-d8 98%
    Hexahydro-1,3-isobenzofurandione-d8 is the deuterium labeled Hexahydroisobenzofuran-1,3-dione (HY-W017331).
    Hexahydro-1,3-isobenzofurandione-d8
  • HY-170246S
    N-Butylbenzenesulfonamide-d9
    N-Butylbenzenesulfonamide-d9 is the deuterium labeled N-Butylbenzenesulfonamide (HY-W014252).
    N-Butylbenzenesulfonamide-d9
  • HY-170265S
    Sulindac methyl ester-d6
    Sulindac methyl ester-d6 is the deuterium labeled Sulindac Impurity 5 (HY-Z12358).
    Sulindac methyl ester-d6
  • HY-170272S
    (E)-Arachidonic acid-d11 1287387-84-1 98%
    (E)-Arachidonic acid-d11 is a deuterated fatty acid.
    (E)-Arachidonic acid-d11
  • HY-170273S
    4-((S)-2,3-Bis(palmitoyloxy)propoxy)-2-(trimethylammonio)butanoate-d9 2260669-85-8 98%
    4-((S)-2,3-Bis(palmitoyloxy)propoxy)-2-(trimethylammonio)butanoate-d9 is a glycerolipid.
    4-((S)-2,3-Bis(palmitoyloxy)propoxy)-2-(trimethylammonio)butanoate-d9
  • HY-17037AS
    Pirenzepine-d11 98%
    Pirenzepine-d11 (LS 519 (free base)-d11; Pirenzepin-d11; Gastrozepin-d11) is the deuterium labeled Pirenzepine (HY-17037A). Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells.
    Pirenzepine-d11
  • HY-17037S1
    Pirenzepine-d8 dihydrochloride 2982740-97-4 98%
    Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells.
    Pirenzepine-d8 dihydrochloride
  • HY-17042AS
    Cetirizine-d4 dihydrochloride 98%
    Cetirizine-d4 (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response.
    Cetirizine-d4 dihydrochloride
  • HY-170905S
    MAT2A-IN-22 2925330-18-1 98%
    MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects.
    MAT2A-IN-22
  • HY-170906S
    MAT2A-IN-23 2925324-58-7 98%
    MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC50 of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP−/−) and in the HCT-116 WT cell line with IC50s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP−/−) and in the HCT-116 WT cell line with IC50s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP−/−) cell proliferation with with an IC50 of 47 nM.
    MAT2A-IN-23
  • HY-172430S
    Epaldeudomide 1918159-31-5 98%
    Epaldeudomide (Compound A406) is the inhibitor for TNF-α (>50% inhibition rate at 100 nM). Epaldeudomide inhibits the proliferation of cancer cells MM.1S (IC50 < 300 nM), WSU-DLCL-2 (IC50 < 100 nM) and Rec-1 (IC50 < 100 nM). Epaldeudomide exhibits antineoplastic activity.
    Epaldeudomide
  • HY-172439S
    Simedeutirom 2403721-24-2 98%
    Simedeutirom is the agonist for thyroid hormone beta receptor (THRβ) and can be used for researchs of metabolic diseases, such as obesity and diabetes mellitus.
    Simedeutirom
  • HY-172733S
    PRMT5-MTA-IN-3-d3 3052146-54-7 98%
    PRMT5-MTA-IN-3-d3 (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d3 is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d3 has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC50 values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d3 has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer.
    PRMT5-MTA-IN-3-d3
  • HY-172836S
    GLP-1 receptor agonist 17-d3 3074098-20-4 98%
    GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
    GLP-1 receptor agonist 17-d3
  • HY-173251S
    ENX-101 98%
    ENX-101 is an orally active (GABAA) receptor partial positive allosteric modulator (PAM). ENX-101 is selective to α2β2γ2L (EC50 = 0.76 nM), α2β3γ2L (EC50 = 0.61 nM), α3 (EC50 = 1.97 nM), α5 (EC50 = 0.85 nM) subunits of GABA receptor. ENX-101 possesses antiseizure activity in several animal models.
    ENX-101
  • HY-17355S2
    Pramipexole-d7-1 dihydrochloride 2702798-58-9 98%
    Pramipexole-d7-1 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole-d7-1 dihydrochloride